CHTR three-lens brief
Evidence-based stock research on CHTR. Three independent lenses — Quality, Momentum, Context — examine live data from SEC filings, the Federal Reserve, and market feeds. Every claim traces to its primary source.
Moved -3.62% yesterday. · Trading at 0% of its 52-week range — deep in the lower band.
- Moved -3.62% yesterday.
- Trading at 0% of its 52-week range — deep in the lower band.
- RSI at 26 — technically oversold.
- Underperforming SPY by 47.3pp over 30 days.
- P/E of 3.9 — trading at a value multiple.
CHTR closed at $142.56 (-3.62%) as of 2026-05-13. Market cap: $20.13B. P/E (trailing) 3.9. Positives: p/E of 3.9 — trading at a value multiple.; analyst mean target $245.31 — 72% above current (16 analysts).. Concerns: moved -3.62% yesterday.; trading at 0% of its 52-week range — deep in the lower band.. Last quarter: Revenue $13.60B, net income $1.16B, free cash flow $2.40B.
Why three lenses on CHTR, not one.
A single reasoning model has blind spots it doesn’t know about. We examine CHTRacross Quality (fundamentals), Momentum (price action and sentiment), and Context (macro/sector). Disagreement between lenses is surfaced, not hidden — it’s how you know when HOLD is the honest call.
Read the full methodologyDrop it in your newsletter or blog.
Free to embed. Updates every 6 hours. Links back to the full brief.
<iframe src="https://clearpathinvest.app/embed/CHTR" width="100%" height="420" frameborder="0" loading="lazy" title="ClearPath CHTR brief"></iframe>